Diploma PLC (LON:DPLM – Get Rating) has been given a consensus recommendation of “Hold” by the seven brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is GBX 3,158 ($41.09).
A number of brokerages have recently weighed in on DPLM. Berenberg Bank reiterated a “buy” rating and set a GBX 3,200 ($41.63) target price on shares of Diploma in a research note on Wednesday, March 23rd. Barclays reiterated an “overweight” rating and set a GBX 3,290 ($42.81) target price on shares of Diploma in a research note on Tuesday, April 12th. Peel Hunt reiterated an “add” rating and set a GBX 3,500 ($45.54) target price on shares of Diploma in a research note on Wednesday, January 19th. Royal Bank of Canada reiterated an “underperform” rating and set a GBX 2,550 ($33.18) target price on shares of Diploma in a research note on Thursday, March 24th. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of Diploma in a research note on Thursday, April 7th.
Shares of LON DPLM opened at GBX 2,794 ($36.35) on Tuesday. The company has a market capitalization of £3.48 billion and a price-to-earnings ratio of 49.80. The company has a debt-to-equity ratio of 47.04, a quick ratio of 0.78 and a current ratio of 1.67. Diploma has a 1-year low of GBX 2,384 ($31.02) and a 1-year high of GBX 3,504 ($45.59). The business’s 50 day moving average price is GBX 2,649.64.
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, rest of Europe, North America, and internationally. It operates through three segments: Life Sciences, Seals, and Controls. The Life Sciences sector supplies consumable and instrument for the diagnostic testing of blood, tissue, and other samples in hospital pathology and life sciences laboratories; electrosurgery equipment and consumable for use in hospital operating room; and surgical medical device, and related consumable and service to GI endoscopy suite in hospital and private clinic.
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.